Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much
one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between
progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical efficacy and safety in the
FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).